217 related articles for article (PubMed ID: 2128723)
1. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
Bode C; Eberle T; Runge M; Haber E; Kübler W
Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
[No Abstract] [Full Text] [Related]
2. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
3. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
[No Abstract] [Full Text] [Related]
4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
5. [Tissue plasminogen activator].
Matsuo O
Rinsho Ketsueki; 1984 Jul; 25(7):1004-10. PubMed ID: 6542154
[No Abstract] [Full Text] [Related]
6. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
Gurewich V
Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
[No Abstract] [Full Text] [Related]
7. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
8. Selective fibrinolytic activity of recombinant non-glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator) from bacteria.
Hanbücken FW; Schneider J; Günzler WA; Friderichs E; Giertz H; Flohé L
Arzneimittelforschung; 1987 Aug; 37(8):993-7. PubMed ID: 3118890
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
10. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
Fry ET; Mack DL; Sobel BE
Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
[TBL] [Abstract][Full Text] [Related]
11. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
Kurokawa T; Iwasa S; Kakinuma A
Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
[TBL] [Abstract][Full Text] [Related]
13. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
14. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
[TBL] [Abstract][Full Text] [Related]
15. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
[No Abstract] [Full Text] [Related]
16. [New thrombolytic agents].
Nguyen G; Samama M
Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
[TBL] [Abstract][Full Text] [Related]
17. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
[TBL] [Abstract][Full Text] [Related]
18. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
19. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
20. [Thrombolytics and their use].
Alessi MC; Juhan-Vague I
Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]